Quebec — DiagnoCure, a life sciences company commercializing high-value cancer diagnostic tests and lab services, has announced the release of its 2010 Annual Report and its availability online at the company’s Web site. This follows a January 19 release of the company’s financial and operation results for the fourth quarter 2010 and fiscal year ended October 31.
The Company announced a net loss of $1,141,903 or $0.03 per share for the fourth quarter, and a net loss of $8,817,417 or $0.21 per share for the fiscal year. These results are in line with nanagement expectations and reflect activities undertaken during the year according to the Company’s plans and ongoing commitment to develop high-value diagnostic tests for the detection and management of cancer. At the end of the quarter, cash, short-term investments and long-term investments stood at $6,904,241.
Click here to download a PDF version of the full annual report.
SOURCE: DiagnoCure
